Fermented milk bases and methods of making fermented milk bases are disclosed. Such fermented milk bases are solid and contain little or no non-dairy stabilizers and non-dairy thickeners. Also disclosed are packaged food products including the disclosed fermented milk bases.

Methods of treating or preventing gestational diabetes mellitus (GDM) and/or treating or preventing one or more GDM-associated risks or one or more sequelae of GDM by administering one or more polar lipids, in addition to uses, compositions, and medicaments comprising one or more polar lipids to treat or prevent gestational diabetes mellitus and/or treat or prevent one or more GDM-associated risks or one or more sequelae of GDM.

A vaginitis pathogen-inhibiting composition comprises a fermentate of lactic acid bacteria, which is generated by jointly fermenting a lactic acid bacteria strain and Streptococcus thermophilus in a medium containing at least one of milk, powdered milk, and casein. The lactic acid bacteria strain includes an AP-32 strain of Lactobacillus salivarius subsp. Salicinius; an F-1 strain of Lactobacillus rhamnosus; a GL-165 strain of Lactobacillus rhamnosus; a CP-9 strain of Bifidobacterium animalis subsp. lactis; a Bf-688 strain of Bifidobacterium bifidum; a Bv-889 strain of Bifidobacterium breve; or combinations thereof. The above-mentioned fermentate of the lactic acid bacteria strain can inhibit growth of vaginitis pathogens and may be in form of a food composition, a pharmaceutical composition, or a vagina-cleaning composition.

Provided is a technique that makes it possible to promote proliferation of probiotics having a low ability to assimilate human milk oligosaccharides (HMOs), in the presence of HMOs. Also provided is a nutritional composition containing bacteria belonging to Bifidobacterium bifidum, one or more types of probiotics having a low ability to assimilate human milk oligosaccharides, and human milk oligosaccharides. The nutritional composition according to the present technology may be suitably used for foods/drinks, medicines, quasi-drugs, feeds, and the like.

A food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose are provided, comprising an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including a GL-104 strain of Lactobacillus reuteri (CCTCC NO: M209138), an AP-32 strain of Lactobacillus salivarius subsp. salicinius (CCTCC NO: M2011127), a TYCA06 strain of Lactobacillus acidophilus (CGMCC No: 15210), and an MH-68 strain of Lactobacillus johnsonii (CCTCC NO: M2011128), or a combination thereof.

The invention relates to a method for producing food products from a yoghurt, the method comprising a step of heating the yoghurt with microwaves at a frequency of between 915 and 2375 MHz and at a temperature of between 60 C. and 65 C. for 10 to 15 seconds, a step of draining the microwave-heated yoghurt, a step of pressing the drained yoghurt then a step of adding at least one emulsifying and/or stabilizing and/or gelling ingredient to the pressed yoghurt.

The present disclosure relates to a method of producing lactic acid bacteria dual-coated with protein and polysaccharide by using a protein hydrolysate, and lactic acid bacteria having a dual coating, produced by the method. The lactic acid bacteria having a dual coating of protein and polysaccharide, produced according to the present disclosure, have very excellent dry-freezing viability, acid resistance and bile resistance. Accordingly, the lactic acid bacteria having a dual coating of protein and polysaccharide according to the present disclosure will be very useful for the production of fermented milk, processed milk, fermented soy products, processed foods, functional beverages, functional foods, common foods, etc.

The present invention relates to a frozen enzyme formulation comprising an enzyme. According to another aspect the present invention relates to a starter culture comprising a frozen enzyme formulation and frozen lactic acid bacteria pellets, wherein the frozen enzyme formulation pellets and the frozen lactic acid bacteria pellets are separate pellets or wherein the enzyme and the lactic acid bacteria are in the same pellets. According to yet another aspect the present invention relates to a method for the production of a frozen enzyme formulation. According to another aspect, the present invention relates to the use of the frozen enzyme formulation.

The invention relates to microcapsules intended to protect probiotics, comprising a shell and a core wherein the probiotics are dispersed in the form of biofilms distributed in distinct clusters, characterised in that the shell and the core are composed of pectin. The invention also relates to the method for manufacturing the capsules, the use thereof, and a formulation comprising the microcapsules according to the invention.

The present invention relates to encapsulation of microbial cultures to improve the robustness and stability upon storage. In particular, the present invention relates to dry preparations of microbial cultures, such as lactic acid bacteria (LAB), coated by a fat-matrix that increase survivability and mitigate post-acidification upon storage at ambient temperature for extended periods of time.